Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Roivant Sciences Ltd. Common Shares (ROIV)

NASDAQ: ROIV · Pharmaceutical Preparations · London,

Our rating: Cautious

Cautious reaffirmed at $41.19, moderate conviction, November 10, 2026.

Breaks if: The cautious call is wrong if Roivant reports quarterly revenue above $50M within the next four quarters — indicating that a pipeline asset has reached meaningful commercial scale — or if the stock sustains above $55 for 20 or more consecutive trading days following a confirmed Phase 3 success or FDA approval that creates a credible near-term revenue stream. Either condition would signal the market correctly priced in pipeline progress that the current financials do not yet reflect.

Key figures

Market value$28.0B
Revenue, last 12 months$41M
Net income, last 12 months−$344M
Free cash flow, last 12 months−$33M
Price to earningsn/a
Free cash flow yield−0.1%
Dividend yield0.0%
Operating margin−1358.1%
Return on equity−8.2%
Beta to the S&P 5000.91
Volatility, annualized38.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$35M2135.6%$-0.27$594M
June 30, 2026$1M−33.5%$-0.26−$271M
March 31, 2026$3M−66.7%$0.34−$165M
December 31, 2025$2M−77.8%$-0.38−$192M
September 30, 2025$2M−64.9%$-0.17−$194M
June 30, 2025$2M−72.8%$-0.33−$208M
March 31, 2025$8M−16.1%$-0.29−$173M
December 31, 2024$9M−42.1%$0.23−$209M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 21 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.